Itoco

Dorzolamide, the active ingredient in Itoco, is a carbonic anhydrase inhibitor presented as an ophthalmic solution for ocular use. It is used to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Itoco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dorzolamide is employed in the management of glaucoma‑related conditions to reduce intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage. Ocular hypertension: reduces eye pressure to lower the risk of developing glaucoma. Secondary glaucoma: helps control pressure when other causes elevate intra‑ocular fluid.

Dorzolamide may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation. - Bitter taste after instillation. - Blurred vision temporarily. - Headache. - Conjunctival hyperemia. - Ocular discomfort.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Corneal edema or ulceration. - Significant vision loss. - Persistent ocular inflammation.

When prescribing or using dorzolamide, consider the following safety measures.

Assess renal function: adjust use in patients with severe renal impairment. Monitor intra‑ocular pressure: ensure therapeutic response and adjust therapy as needed. Avoid in sulfonamide‑allergic patients: consider alternative agents. Inform patients about transient visual disturbances: advise reporting persistent changes. Store at room temperature: keep in the original container, protect from light and moisture.

Dorzolamide can interact with other ocular or systemic medications.

Major Interactions (Avoid): - Acetazolamide: additive intra‑ocular pressure‑lowering effect may cause excessive reduction. - Topical beta‑blockers: combined use can lead to overly low ocular pressure.

Moderate Interactions (Monitor Closely): - Systemic sulfonamides: potential cross‑reactivity; monitor for allergic signs. - Prostaglandin analogues: may influence overall pressure‑lowering efficacy; observe IOP. - Anticholinergic eye drops: may increase ocular irritation; assess patient comfort.